Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) have been assigned an average rating of “Hold” from the thirteen ratings firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and six have assigned a buy recommendation […]
PTC Therapeutics (NASDAQ:PTCT – Get Free Report) and Olema Pharmaceuticals (NASDAQ:OLMA – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations. Analyst Recommendations This is a breakdown of recent […]
StockNews.com started coverage on shares of PTC Therapeutics (NASDAQ:PTCT – Free Report) in a research report report published on Thursday morning. The firm issued a hold rating on the biopharmaceutical company’s stock. A number of other research firms have also commented on PTCT. Bank of America raised their price objective on shares of PTC Therapeutics […]
PTC Therapeutics (NASDAQ:PTCT – Get Free Report)‘s stock had its “buy” rating reiterated by Truist Financial in a research note issued on Wednesday, Benzinga reports. They currently have a $65.00 price objective on the biopharmaceutical company’s stock. Truist Financial’s price target points to a potential upside of 59.82% from the company’s current price. Several other […]
PTC Therapeutics (NASDAQ:PTCT – Get Free Report)‘s stock had its “overweight” rating reiterated by Cantor Fitzgerald in a research report issued to clients and investors on Monday, Benzinga reports. They currently have a $73.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target suggests a potential upside of 85.80% from the company’s previous […]